Abstract
NO is a key signaling molecule that has a wide range of biological functions including vasodilation and neurotransmission, and is implicated in several pathological conditions. Therefore, modulation of NO is a desired step in curbing the NO-associated disease processes. Targetting NOS proteins and inhibiting their activity to reduce NO production is a major approach since the inception of NOS inhibitor research. Although a series of NOS inhibitors have been developed, synthesized and practiced in experimental biology, no NOS inhibitor has been approved as yet a drug for therapeutic uses. The present review elaborates the scope of the clinical uses of NOS inhibitors and the inherent limitations of the process that makes the approach less successful so far in clinic.
Keywords: Nitric Oxide (NO), Nitric Oxide Synthase (NOS), Nitric Oxide Synthase inhibitors, NOS oxidase domain, NOS reductase domain.
Current Enzyme Inhibition
Title:Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Volume: 12 Issue: 1
Author(s): Lakshmikirupa Sundaresan, Suvendu Giri and Suvro Chatterjee
Affiliation:
Keywords: Nitric Oxide (NO), Nitric Oxide Synthase (NOS), Nitric Oxide Synthase inhibitors, NOS oxidase domain, NOS reductase domain.
Abstract: NO is a key signaling molecule that has a wide range of biological functions including vasodilation and neurotransmission, and is implicated in several pathological conditions. Therefore, modulation of NO is a desired step in curbing the NO-associated disease processes. Targetting NOS proteins and inhibiting their activity to reduce NO production is a major approach since the inception of NOS inhibitor research. Although a series of NOS inhibitors have been developed, synthesized and practiced in experimental biology, no NOS inhibitor has been approved as yet a drug for therapeutic uses. The present review elaborates the scope of the clinical uses of NOS inhibitors and the inherent limitations of the process that makes the approach less successful so far in clinic.
Export Options
About this article
Cite this article as:
Sundaresan Lakshmikirupa, Giri Suvendu and Chatterjee Suvro, Inhibitors of Nitric Oxide Synthase: What's up and What's Next?, Current Enzyme Inhibition 2016; 12 (1) . https://dx.doi.org/10.2174/1573408012666151126185922
DOI https://dx.doi.org/10.2174/1573408012666151126185922 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mobile Phone Text Message Interventions in Psychiatry - What are the Possibilities?
Current Psychiatry Reviews Toll-like Receptor 4 Mediates LPS-Induced Release of Nitric Oxide and Tumor Necrosis Factor-α by Embryonal Cardiomyocytes: Biological Significance and Clinical Implications in Human Pathology
Current Pharmaceutical Design The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Cytotoxic Potential of Phenothiazines
Current Drug Targets The Metabolism of Methazolamide - Identification of Metabolites in Guinea Pig Urine
Drug Metabolism Letters Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease
Mini-Reviews in Medicinal Chemistry Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Bioactive Proteins and Peptides from Food Sources. Applications of Bioprocesses used in Isolation and Recovery
Current Pharmaceutical Design Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design